Medication Use Evaluation of Dronedarone in Comparison to Amiodarone
Amiodarone is the most effective rhythm-control for atrial fibrillation, but produces serious potential side effects. Dronedarone was designed to eliminate amiodarone toxicities, but increased the risk of mortality in clinical trials. This medication use evaluation compares one year of dronedarone u...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University of Minnesota Libraries Publishing
2016-12-01
|
| Series: | INNOVATIONS in Pharmacy |
| Subjects: | |
| Online Access: | https://pubs.lib.umn.edu/index.php/innovations/article/view/480 |
| _version_ | 1811276866228584448 |
|---|---|
| author | Adam Corey Nita Johnston |
| author_facet | Adam Corey Nita Johnston |
| author_sort | Adam Corey |
| collection | DOAJ |
| description | Amiodarone is the most effective rhythm-control for atrial fibrillation, but produces serious potential side effects. Dronedarone was designed to eliminate amiodarone toxicities, but increased the risk of mortality in clinical trials. This medication use evaluation compares one year of dronedarone use with a matched cohort of amiodarone patients at a single hospital in Greensboro, NC. Forty-eight patients were included with an average age of 71.8 years and 37.5% female population. No significant difference was found for the primary composite outcome of death, myocardial infarction, stroke, and systemic embolism (OR = 2.4, p = 0.148). Likewise, no statistical significance was demonstrated between the two groups for QTc prolongation, hypothyroidism, liver dysfunction or maintenance of normal sinus rhythm. In conclusion, the clinical decision process demonstrated no increased risk of death or other adverse events in the use of dronedarone.
Conflict of Interest
We declare no conflicts of interest or financial interests that the authors or members of their immediate families have in any product or service discussed in the manuscript, including grants (pending or received), employment, gifts, stock holdings or options, honoraria, consultancies, expert testimony, patents and royalties
Type: Student Project |
| first_indexed | 2024-04-13T00:05:29Z |
| format | Article |
| id | doaj.art-1ef162f3c86c45f6b6acb51f1bc552ab |
| institution | Directory Open Access Journal |
| issn | 2155-0417 |
| language | English |
| last_indexed | 2024-04-13T00:05:29Z |
| publishDate | 2016-12-01 |
| publisher | University of Minnesota Libraries Publishing |
| record_format | Article |
| series | INNOVATIONS in Pharmacy |
| spelling | doaj.art-1ef162f3c86c45f6b6acb51f1bc552ab2022-12-22T03:11:14ZengUniversity of Minnesota Libraries PublishingINNOVATIONS in Pharmacy2155-04172016-12-017410.24926/iip.v7i4.480Medication Use Evaluation of Dronedarone in Comparison to AmiodaroneAdam Corey0Nita Johnston1University of North Carolina Eshelman School of PharmacyMoses H. Cone HospitalAmiodarone is the most effective rhythm-control for atrial fibrillation, but produces serious potential side effects. Dronedarone was designed to eliminate amiodarone toxicities, but increased the risk of mortality in clinical trials. This medication use evaluation compares one year of dronedarone use with a matched cohort of amiodarone patients at a single hospital in Greensboro, NC. Forty-eight patients were included with an average age of 71.8 years and 37.5% female population. No significant difference was found for the primary composite outcome of death, myocardial infarction, stroke, and systemic embolism (OR = 2.4, p = 0.148). Likewise, no statistical significance was demonstrated between the two groups for QTc prolongation, hypothyroidism, liver dysfunction or maintenance of normal sinus rhythm. In conclusion, the clinical decision process demonstrated no increased risk of death or other adverse events in the use of dronedarone. Conflict of Interest We declare no conflicts of interest or financial interests that the authors or members of their immediate families have in any product or service discussed in the manuscript, including grants (pending or received), employment, gifts, stock holdings or options, honoraria, consultancies, expert testimony, patents and royalties Type: Student Projecthttps://pubs.lib.umn.edu/index.php/innovations/article/view/480Dronedarone, Amiodarone, Medication Use Evaluation, Atrial Fibrillation |
| spellingShingle | Adam Corey Nita Johnston Medication Use Evaluation of Dronedarone in Comparison to Amiodarone INNOVATIONS in Pharmacy Dronedarone, Amiodarone, Medication Use Evaluation, Atrial Fibrillation |
| title | Medication Use Evaluation of Dronedarone in Comparison to Amiodarone |
| title_full | Medication Use Evaluation of Dronedarone in Comparison to Amiodarone |
| title_fullStr | Medication Use Evaluation of Dronedarone in Comparison to Amiodarone |
| title_full_unstemmed | Medication Use Evaluation of Dronedarone in Comparison to Amiodarone |
| title_short | Medication Use Evaluation of Dronedarone in Comparison to Amiodarone |
| title_sort | medication use evaluation of dronedarone in comparison to amiodarone |
| topic | Dronedarone, Amiodarone, Medication Use Evaluation, Atrial Fibrillation |
| url | https://pubs.lib.umn.edu/index.php/innovations/article/view/480 |
| work_keys_str_mv | AT adamcorey medicationuseevaluationofdronedaroneincomparisontoamiodarone AT nitajohnston medicationuseevaluationofdronedaroneincomparisontoamiodarone |